Pemeriksaan Antibodi Paska Vaksinasi COVID-19 pada Penduduk di Sekitar Universitas Jenderal Achmad Yani

Patricia Naully; Perdina  Nursidika; Prina Puspa  Kania; Firdha  Rachmawati; Taufik  Gunawan

doi:10.29407/ja.v6i3.16772

Authors

Patricia Naully Universitas Jenderal Achmad Yani
Perdina Nursidika Universitas Jenderal Achmad Yani
Prina Puspa Kania Universitas Jenderal Achmad Yani
Firdha Rachmawati Universitas Jenderal Achmad Yani
Taufik Gunawan Universitas Jenderal Achmad Yani

DOI:

https://doi.org/10.29407/ja.v6i3.16772

Keywords:

Antibody, COVID-19, Vaccination.

Abstract

In order to reduce the incidence of COVID-19, the Ministry of Health has thoroughly vaccinated including residents around Jenderal Achmad Yani University, but they don’t know the number of antibodies formed after the COVID-19 vaccination. This activity aims to provide information to residents around UNJANI regarding the number of specific antibodies that their bodies have successfully formed after the COVID-19 vaccination. A total of 50 local residents who have received the COVID-19 vaccination were invited to take part in this activity. Specific antibodies in the participants' blood were examined using the Enzyme Linked Immunosorbent Assay (ELISA) method. The results that have been validated by doctors are informed to the participants. Through laboratory examination, it was found that 66% of participants succeeded in forming specific antibodies above 7 U/ml and 34% of participants below 7 U/ml. The target of this activity has been achieved, residents around UNJANI can find out the number of specific antibodies they have successfully formed after the COVID-19 vaccination.

Downloads

Download data is not yet available.

References

Banoun, H. (2021). Evolution of SARS-CoV-2: Review of Mutations, Role of the Host Immune System. Nephron, 145(4), 392–403. https://doi.org/10.1159/000515417

Cheng, Z. J., Xue, M., Zheng, P., Lyu, J., Zhan, Z., Hu, H., Zhang, Y., Zhang, X. D., & Sun, B. (2021). Factors Affecting the Antibody Immunogenicity of Vaccines against SARS-CoV-2: A Focused Review. Vaccines, 9(8), 869. https://doi.org/10.3390/vaccines9080869

Chiu, S.-K., Tsai, K.-W., Wu, C.-C., Zheng, C.-M., Yang, C.-H., Hu, W.-C., Hou, Y.-C., Lu, K.-C., & Chao, Y.-C. (2021). Putative Role of Vitamin D for COVID-19 Vaccination. International Journal of Molecular Sciences, 22(16), 8988. https://doi.org/10.3390/ijms22168988

Cucunawangsih, C., Wijaya, R. S., Lugito, N. P. H., & Suriapranata, I. (2021). Antibody response to the inactivated SARS-CoV-2 vaccine among healthcare workers, Indonesia. International Journal of Infectious Diseases, 113, 15–17. https://doi.org/10.1016/j.ijid.2021.09.078

Direktorat Kesehatan dan Gizi Masyarakat. (2021). Proyeksi COVID-19 di Indonesia. Direktorat Kesehatan dan Gizi Masyarakat.

Jayani, I., Ramayanti, E. D., & Susmiati, S. (2021). Edukasi Penerapan Protokol Kesehatan Pada Era New Normal Sebagai Bentuk Upaya Pencegahan Pengendalian Covid-19. Jurnal ABDINUS : Jurnal Pengabdian Nusantara, 5(1), 1–8. https://doi.org/10.29407/ja.v5i1.15270

Kementerian Kesehatan Republik Indonesia. (2020). Protokol Kesehatan Bagi Masyarakat di Tempat Umum. Kementerian Kesehatan Republik Indonesia.

Kementerian Kesehatan Republik Indonesia. (2021). Situasi Terkini Perkembangan Coronavirus Disease (COVID-19). Kementerian Kesehatan Republik Indonesia.

Khoury, J., Najjar-Debbiny, R., Hanna, A., Jabbour, A., Abu Ahmad, Y., Saffuri, A., Abu-Sinni, M., Shkeiri, R., Elemy, A., & Hakim, F. (2021). COVID-19 vaccine – Long term immune decline and breakthrough infections. Vaccine, 39(48), 6984–6989. https://doi.org/10.1016/j.vaccine.2021.10.038

McNeil, S. (2006). Overview of Vaccine Efficacy and Vaccine Effectiveness. WHO, 19.

Satuan Tugas Penanganan COVID-19 Republik Indonesia. (2021). Analisis Data COVID-19 Indonesia. Satuan Tugas Penanganan COVID-19 Republik Indonesia.

World Health Organization. (2020). Corona Disease (COVID-19) Situation Report—198. World Health Organization.

World Health Organization. (2021). Interim recommendations for use of the inactivated COVID-19 vaccine, CoronaVac, developed by Sinovac. World Health Organization.

Wu, Z., Hu, Y., Xu, M., Chen, Z., Yang, W., Jiang, Z., Li, M., Jin, H., Cui, G., Chen, P., Wang, L., Zhao, G., Ding, Y., Zhao, Y., & Yin, W. (2021). Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: A randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. The Lancet Infectious Diseases, 21(6), 803–812. https://doi.org/10.1016/S1473-3099(20)30987-7

Zimmermann, P., & Curtis, N. (2019). Factors That Influence the Immune Response to Vaccination. Clinical Microbiology Reviews, 32(2). https://doi.org/10.1128/CMR.00084-18